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Abstract In the present study, we investigated the anti-
inflammatory mechanisms by which gabapentin
enhances morphine anti-nociceptive effect in neuropathic
pain in rats and the interaction between the anti-
nociceptive effects of gabapentin on morphine and the
interleukin (IL)-10-heme-oxygenase (HO)-1 signal path-
way in a rat model of neuropathic pain. The neuropathic
pain model was induced via a left L5/6 spinal nerve
ligation (SNL) in rats. The anti-nociceptive effect of
gabapentin and IL-10 on morphine was examined over
a 7-day period, and the effects of the anti-IL-10 and
HO-1 inhibitor zinc protoporphyrin (ZnPP) on
gabapentin/morphine co-injection were assessed. Drug
administration was given over 7 days, and on day 8,
both anti-inflammatory cytokine IL-10, a stress-induced
protein HO-1 and pro-inflammatory cytokines IL-1β,
IL-6 and TNF-α were measured. Gabapentin attenuated
morphine tolerance over 7 days of co-administration,
and reduced the expression of pro-inflammatory cyto-
kines but increased IL-10 and HO-1 expression. The
effect of gabapentin on morphine was partially blocked
using the anti-IL-10 antibody or the HO-1 inhibitor zinc
protoporphyrin. Our findings indicated that the anti-
nociceptive effects of gabapentin on morphine might
be caused by activation of the IL-10-HO-1 signalling
pathway, which resulted in the inhibition of the expres-
sion of pro-inflammatory cytokines in neuropathic pain
in the rat spinal cord.
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Introduction
Neuropathic pain remains a serious clinical problem due
to the lack of efficacy of available therapeutic modali-
ties. Using opioids to control neuropathic pain has
proven to be effective in animals and humans, chal-
lenges with analgesic tolerance have limited its use.
The mechanism underlying opioid tolerance is complex
and poorly understood particularly under conditions of
neuropathic pain. Thus, a deeper understanding of the
mechanisms underlying morphine tolerance under
conditions of neuropathic pain may contribute to the
development of better analgesic treatments for pain.
Previous studies have demonstrated that both pro-
inflammatory and anti-inflammatory cytokines are
involved in the establishment and maintenance of mor-
phine tolerance and neuropathic pain (Johnston et al.
2004; Schafers and Sommer 2007; Uceyler and
Sommer 2008; Shen et al. 2011). Opioids-induced
hyperalgesia is observed in tolerance; it is similar to
the symptoms observed in neuropathic pain, where
opioids also have a limited analgesic effect (Mika
et al. 2004; Narita et al. 2013). Numerous studies have
indicated that neuropathic pain results in reduced
morphine efficacy and a more rapid development of
morphine tolerance (Ossipov et al. 1995; Mayer et al.
1999; Mika et al. 2004; Przewlocki and Przewlocka
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2005). It has been shown that the suppression of glial
activation, which in turn, inhibits pro-inflammatory cyto-
kine synthesis, can improve morphine efficacy in treating
neuropathic pain (Song and Zhao 2001; Raghavendra et al.
2002; Watkins et al. 2007). IL-10 is a powerful anti-
inflammatory cytokine with a wide spectrum of biological
effects. A previous study has shown that the anti-
inflammatory cytokine IL-10 exhibits anti-allodynic or
anti-hyperalgesic effects by inhibiting the release of the
pro-inflammatory cytokines TNF-α and IL-1β via the
peritoneal macrophages (Laughlin et al. 2000; Wang et al.
2012). IL-10 not only demonstrates an anti-nociceptive
effect in neuropathic pain rats with spared nerve injury
but also plays a pivotal role in morphine tolerance, via its
regulation of the production of pro-inflammatory cytokines
and nerve growth factor. Several studies have demonstrated
that acute administration of 5, 10 and 20 mg/kg morphine
decreased the expression of IL-10 in a dose-dependent
manner (Limiroli et al. 2002). In addition, daily intrathecal
(i.t.) injection of 1 μg of rrIL-10 significantly preserved the
anti-nociceptive effects of morphine in chronic morphine-
infused rats. Moreover, gene therapy with an adenoviral
vector encoding IL-10 potentiated acute morphine
analgesia and attenuated the development of morphine
tolerance (Sacerdote 2003; Lin et al. 2010). Additional
studies have demonstrated that the powerful anti-
inflammatory effect of IL-10 is associated with heme-
oxygenase (HO)-1. In murine macrophages, IL-10 induces
the expression of HO-1, a stress-induced protein with a
potent anti-inflammatory effect, which enhances the anti-
inflammatory capacity of IL-10, and anti-10 antibody
reversed the amitriptyline-induced upregulation of HO-1
expression in morphine-tolerant rats (Drechsler et al.
2006; Tai et al. 2009).
Gabapentin is also used as an anti-convulsant drug and is
now widely becoming accepted as an alternative treatment for
various types of neuropathic and inflammatory pain
(Boroujerdi et al. 2011; Thomas and Farquhar-Smith 2011;
Yeh et al. 2011). Gabapentin also has a well-established role in
the attenuation of morphine tolerance. Previous preclinical
studies have demonstrated that gabapentin increases the anti-
nociceptive effect of morphine in an acute model of
nociception and in a visceral nociception model (Meymandi
and Sepehri 2008). An electrophysiological study showed that
this combination inhibited evoked dorsal horn neuronal re-
sponses in a rat model of neuropathy (Matthews and
Dickenson 2002). However, the mechanism of the gabapentin
enhancement of morphine-induced anti-nociceptive effect in a
neuropathic pain model is not very well understood. In our
previous studies, we found that gabapentin-attenuated mor-
phine tolerance is associated with the upregulation of spinal
anti-inflammatory cytokine IL-10 and downregulation of pro-
inflammatory cytokines TNF-α, IL-1β and IL-6. Byung-Sang
et al. found that the anti-nociceptive effects of gabapentin
might be caused by an upregulation of IL-10 expression,
which results in the inhibited expression of pro-
inflammatory cytokines in neuropathic pain rats (Lee et al.
2013). Thus, inflammatory mechanisms play an important
role in the gabapentin rescue of the anti-nociceptive effects
of morphine.
In our present study, we examined the potential mechanism
underlying the effect of gabapentin on the inhibition of spinal
cord neuroinflammation. We hypothesised that gabapentin
enhanced the morphine anti-nociceptive effect via IL-10 and
its downstream HO-1 signal transduction pathway to inhibit
pro-inflammatory cytokine expression in neuropathic pain
rats. Taken together, our results provide insight for the role
of gabapentin in clinical pain management, particularly in




The experiments were performed on male Sprague–Dawley
rats (200–250 g) provided by the Shanghai Laboratory Ani-
mal Center at the Chinese Academy of Science (Shanghai,
China) and were approved by the Animal Care and Use
Committee of the Medical School of the Shanghai Jiao Tong
University. The rats were individually housed after i.t. cathe-
terisation. Food and water were available ad libitum. The
temperature and relative humidity were maintained at 23±
1 °C and 50–55 %, respectively. The animal room was artifi-
cially maintained on a 12-h light/12-h dark cycle (lights on
08:00–20:00 h).
Intrathecal Catheterisation
For i.t. drug administration, the rats were anesthetised with
pentobarbital (50 mg/kg, intraperitoneal) using a PE-10 i.t.
catheter (Becton Dickinson, Sparks, MD, USA), which was
inserted via an incision in the atalanto-occipital membrane of
the cisterna magna such that the tip of the catheter is placed at
the lumbar enlargement. The bead end was cut each time prior
to i.t. injection and was fixed for the next use. The rats were
allowed to rest for 1 day after catheterisation, and lidocaine
(2 %, 10 μl) was subsequently injected through the catheter to
test its position. Only the rats that showed immediate paralysis
on both sides (30 s) after lidocaine injection were kept in the
study. The drugs were injected through the i.t. catheter. After a
recovery period of 7 days, the animals without locomotion
deficits were subjected to the neuropathic pain model (n=6
each group).
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Neuropathic Pain Models
One week after i.t. injection, ligation of the L5/6 spinal nerves
in rats was used as an experimental model of neuropathic pain
in this study, which was performed according to the method
previously described by Kim and Chung (1992). All animals
were anaesthetised with sodium pentobarbital (50 mg/kg,
intraperitoneally). A dorsal midline incision was made from
L3 to S2 and the left L5 and L6 spinal nerve were isolated and
tightly ligated with 4-0 silk sutures. The incision was then
closed in two layers. The sham surgery involved the sham
procedure but without nerve ligation. Only animals presenting
with confirmed tactile allodynia and exhibiting no motor
weakness were used for this experiment. After surgery, each
rat was injected intraperitoneally with penicillin 0.2 million
units per day for 6 consecutive days (n=6 each group).
Drugs and Treatment
All animal experiments were performed on day 7 after the
spinal nerve ligation (SNL) model established. Recombinant
rat IL-10 (rrIL-10; 1, 2 and 5 μg in 10 μl; Cell Science,
Canton, MA, USA), anti-IL-10 antibody (1, 5 and 10 μg in
10 μl; Abcam), HO-1 antagonist zinc protoporphyrin (ZnPP;
24 μg in 10 μl; Tocris Cookson, Bristol, UK), morphine
(30 μg in 5 μl; Yichang, China) and gabapentin (25 μg in
5 μl, Sigma). All drugs were dissolved in 0.9 % saline and
were administered twice a day for 7 days via a PE-10 injection
using a microinjector, followed by a 10-μl physical flush.
When two or three drugs were co-administered, there was a
1–2 μl air in the syringe to separate them. Doses of
gabapentin, recombinant rat IL-10, anti-IL-10 antibody and
Znpp were selected on the basis of previous studies and our
preliminary studies. All of these drugs when administered
alone had no effect on neuropathic pain in rats. The doses of
morphine were chosen on the basis of our preliminary work,
which demonstrated that 30 μg had an anti-nociceptive effect
on neuropathic pain rats. Animals were randomly placed into
either the drug or vehicle groups according to baseline testing,
and the testing was performed in a blind manner. Behavioural
tests were performed at 30 min after each daily drug injec-
tions. All rats in each group were sacrificed after the 7-day
course of treatment for tissue extraction (n=6 each group).
Behavioural Analysis
Seven days after establishing the neuropathic pain model,
behavioural testing was performed. All rats were habituated
in the experimental arena. Nociceptive testing was initially
performed using the tail–flick test and then with the paw-
withdrawal test. Animal behavioural testing was measured
30 min after the first drug was administered each day. The
investigator was blind to the treatment condition of the rats.
Tail–Flick Test
Thermal hyperalgesia was assessed using the tail–flick test
according to the method described by Vanderah et al. This test
was performed in a warm water (52.5±0.5 °C) tail–flick
apparatus (Shanghai Thermo-stat Factory, Shanghai, China).
The nociceptive endpoints were the characteristic withdrawal
of the tail from the warm water. To avoid tissue damage, the
heat stimulus was discontinued after 10 s (cut-off latency).
The baseline latency was obtained before any drugs were
used. The following response latencies were determined at
30 min after the administration of the drug(s). Tail–flick
values were converted to a maximum percent effect (MPE):
MPE=100×[(post-drug latency-baseline)/(cut-off latency-
baseline)] (n=6 each group).
Von Frey Test
Mechanical hyperalgesia in rats was measured using a series
of calibrated nylon Von Frey filaments (Stoelting, Wood Dale,
IL, USA) ranging from 0.4 to 26 g. The Von Frey filaments
were applied in ascending order to the mid-plantar surface of
the operated hind paw through the mesh floor. Brisk with-
drawal or paw flinching were considered positive responses.
Each probe was applied to the foot until it started to bend. The
paw withdrawal threshold (PWT) was calculated using the
‘up–down’ method, and these data were analysed using the
nonparametric method of Dixon as described by Chaplan et al.
(1994). An examiner who was blind to the treatment groups
performed all of the behavioural tests (n=6 each group).
Enzyme-Linked Immunosorbent Assay
On day 8, all of the rats were sacrificed following an overdose
of pentobarbital anaesthesia. The L4–L6 left-half of the spinal
cord was immediately removed and stored at -80 °C prior to
further treatment. Frozen samples were directly homogenised
in a buffer in the presence of protease inhibitors (Sigma). After
centrifugation at 13,000 rpm for 20 min, the supernatant was
obtained for IL-1, IL-6, TNF-α and IL-10 protein analysis.
The Bradford protein assay was used to determine the total
protein concentration. Commercially available enzyme-linked
immunosorbent assay (ELISA) kits were used to assess the
cytokine proteins (R&D Systems, Minneapolis, MN, USA;
sensitivity: 5 pg/ml). ELISA microplates were analysed using
a Victor3 V multilabel counter (1420, Perkin-Elmer, Boston,
MA, USA), and data were standardised as picograms of
TNF-α, IL-1β, IL-6 and IL-10 per 200 μg of total supernatant
protein. The concentration of each target cytokine was deter-
mined based on an appropriate set of internal standard curves
using recombinant rat cytokines (n=6 each group).
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Western Blotting Analyses
Frozen samples were directly homogenised in a buffer
(Beyotime, Nanjing, Jiangsu, China) in the presence of prote-
ase inhibitors (Sigma-Aldrich, USA). After centrifugation at
12,000 rpm for 30 min at 4 °C, the supernatant was obtained
for Western blotting analysis. BCA (Pierce, Thermo Fisher
Scientific, Waltha, MA) methods were used to assay the
protein concentration. The total protein (50 μg) was loaded
onto a 10 % sodium dodecyl sulphate (SDS) polyacrylamide
gel and transferred onto polyvinylidene difluoride (PVDF)
membranes (Millipore, Billerica, MA, USA) for Western blot-
ting analyses. The membranes were blocked with 10 % non-
fat milk in Tris-buffered saline (TBS) for 2 h at room temper-
ature (RT) and incubated with antibodies overnight at 4 °C
with monoclonal mouse anti-HO-1 (1:2000, Abcam) antibody
or goat anti-β actin (1:10000, Sigma) primary antibodies. The
membranes were washed with TBS containing 1 % Tween
and incubated with horseradish peroxidase-conjugated sec-
ondary antibodies (1:2,500; donkey anti-rabbit; Cell Signal-
ing, USA) for 1 h at room temperature. Finally, the proteins
were detected using electrochemiluminescence reagents
(Pierce Biotechnology, Rockford, IL, USA) and visualised
by film exposure. The protein band density was quantified
using densitometric scanning. All Western blotting analyses
were performed at least three times, and parallel results were
recorded (n=6 each group).
Statistical Analysis
All values were presented as the mean±standard error (SEM)
and analysed using Graphpad Prism software. The SNLmodel
of Von Frey filament test was determined using nonlinear
regression analysis followed by one-way analysis of variance
(ANOVA) analysis. For 7 days, behavioural tests were
analysed using a two-way repeated-measures analysis of var-
iance (treatment by time). For statistical analysis, immunore-
activity and cytokine data were analysed using one-way
ANOVA followed by multiple comparisons using the Stu-
dent–Newman–Keuls post hoc test. p<0.05 was considered
statistically significant.
Results
The Established SNL Model
As shown in Fig. 1, 1 week after SNL, the mechanical with-
drawal threshold of the hind paw ipsilateral to the nerve injury
was significantly decreased in SNL rats (p<0.001) compared
to the sham-operated animals. In addition, no difference in the
withdrawal threshold was observed in the contralateral hind
paw. These results suggested that the neuropathic pain model
with monolateral mechanical allodynia has been successfully
established and was consistent with previous reports.
Effects of Gabapentin and Anti-IL-10 Antibody on Morphine
Administration in SNL Rats
In SNL rats, chronic morphine tolerance was attenuated by co-
administration of gabapentin with morphine twice a day for
7 days in the behavioural tests (Fig. 2b, c). The efficacy of
morphine was diminished after 4 days of injection, but the
efficacy was maintained on day 7 when morphine was co-
administered with gabapentin. The anti-IL-10 antibody
abolished the effect of gabapentin on morphine. Moreover,
there was no difference in anti-nociception effect in the saline
group or the gabapentin and anti-IL-10 antibody-treated
animals.
On day 8, analysis of the lumbar spinal cord homogenates
demonstrated that an i.t. daily injection of anti-IL-10 antibody
(10 μg) alone did not affect IL-10 expression compared with
the saline-injected rats (Fig. 2a). Furthermore, co-injection of
gabapentin (25 μg)/morphine (30 μg) clearly increased the
anti-inflammatory cytokine IL-10 protein levels compared to
that in the saline-, gabapentin- and morphine-injected
rats. Daily injection of anti-IL-10 antibody significantly
neutralised the effect of gabapentin in the morphine-
injected rats.
Effects of IL-10 Regarding the Improvement
of the Anti-Nociceptive Effect of Morphine in Neuropathic
Pain Rats
Recombinant rat IL-10 (rrIL-10) was used to investigate the
effect of IL-10 in the attenuation of the development of
morphine tolerance. Daily intrathecally injections of rrIL-10
(5 μg) alone did not produce any anti-nociceptive effect via
the 7-day treatment compared with the saline group
Fig. 1 Time course of paw withdrawal threshold after spinal nerve
ligation (SNL) and sham surgery over a 7-day period. All data points
are expressed as the mean±SEM (n=6, each). *p<0.05, ***p<0.001
compared with sham group
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(Fig. 3a, b). The anti-nociceptive effect of continuous mor-
phine injection was partially maintained via a daily intrathecal
rrIL-10 (5 μg) injection during tolerance induction but not
by an injection of lower doses of rrIL-10 (1 or 2 μg)
compared with the morphine group. These data demonstrated
that IL-10 attenuated morphine tolerance in neuropathic pain
rats.
Anti-IL-10 Antibody-Induced Effects of HO-1 Expression
Are Dose-Dependent
Co-injection of gabapentin and morphine for 7 days signifi-
cantly increased HO-1 expression compared with the
morphine-treated animal group (Fig. 4). In addition, daily i.t.
injection of different doses of anti-IL-10 antibody for 7 days
dose-dependently reversed the gabapentin-induced upregula-
tion of HO-1 expression. These results suggested that IL-10 is
involved in the increase in HO-1 expression in gabapentin/
morphine–injected neuropathic pain rats.
Role of the HO-1 Inhibitor ZnPP in Reversing Gabapentin
Enhancement of Morphine Anti-Nociceptive Effects
in Neuropathic Pain Rats
Daily i.t. injection of the HO-1 antagonist zinc protoporphyrin
(ZnPP) with gabapentin/morphine in neuropathic pain rats for
Fig. 2 Il-10 anti-body abolished the effect of gabapentin on morphine in
SNL exposed rats. a IL-10 protein levels were measured in the experi-
mental group. Co-administration of gabapentin (25 μg) with morphine
(30 μg) for 7 days twice daily significantly increased IL-10 expression in
rats; anti-IL-10 antibody (10 μg) neutralised IL-10 expression induced by
this co-administration; gabapentin delayed morphine tolerance develop-
ment in SNL-exposed rats, as measured using the tail–flick (b) and Von
Frey (c) tests. Themaximum anti-nociceptive effect ofmorphine occurred
on days 1–3. From days 4 to 7, there was no difference between the
morphine and saline groups. When gabapentin was co-administered with
morphine and prevented morphine tolerance. The anti-IL-10 antibody
partially reversed the potentiating effect of gabapentin on morphine in
SNL rats (n=6, each). ***p<0.001 compared with the saline group;
###p<0.001 compared with the morphine group; $p<0.05, $$p<0.01,
$$$p<0.001 compared with the gabapentin/morphine group
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7 days reversed the upregulation of HO-1 expression in
gabapentin/morphine injected rats (Fig. 5a). In addition, it
blocked the maintenance of morphine’s anti-nociceptive effect
by gabapentin in SNL rats. Consistent with these results, the
maximal anti-nociceptive effect of morphine was observed on
day 1, and the maximal tolerance was observed on day 4 in
morphine-injected rats. Co-administration of ZnPP with
gabapentin plus morphine blocked the maintenance of mor-
phine’s anti-nociceptive effect by gabapentin and decreased
the expression of HO-1 in spinal cords from day 3 to day 7
(Fig. 5b, c).
Inhibition of IL-10 Expression and HO-1 Expression
Reverses the Suppressive Effects of Gabapentin on Cytokine
Production in Morphine-Injected SNL Rats
As shown in Fig. 6, protein levels for the pro-inflammatory
cytokines IL-1β, IL-6 and TNF-αwere significantly increased
in morphine-injected rats compared with the saline-injected
rats, and this effect was significantly attenuated by gabapentin
co-injection. Furthermore, injection of anti-IL-10 antibody and
the HO-1 antagonist ZnPP significantly abolished the suppres-
sive effect of gabapentin on pro-inflammatory cytokine pro-
duction in morphine-injected SNL rats.
Discussion
In the present study, over 7 days, chronic morphine injection
produced anti-nociceptive tolerance in an SNL rat model of
neuropathic pain. In addition, gabapentin enhanced the anti-
nociceptive effect of morphine. This effect could be ex-
plained, at least in part , by gabapentin-induced
Fig. 3 Effects of IL-10 on the anti-nociceptive effects of morphine in
SNL rats. Time-course of the tail–flick (a) and Von Frey filament (b) tests
after 7 days of daily injection of various doses (1, 2 or 5 μg) of recom-
binant rat IL-10 (rrIL-10) combined with continuous i.t. morphine injec-
tion. A large dose injection of rrIL-10 (5 μg) with morphine for 7 days
produced a significantly anti-nociceptive effect, whilst rrIL-10 (5 μg)
administered alone did not produce an anti-nociceptive effect in SNL rats
(n=6, each). ***p<0.001 compared with the saline group; ###p<0.001
compared with the morphine group
Fig. 4 Anti-IL-10 antibody dose-dependently reversed gabapentin-
induced heme oxygenase-1 (HO-1) expression in gabapentin/morphine
co-injected SNL rats. Western blotting analyses of HO-1 in the spinal
cord dorsal horn of the various treatment groups; β-actin was used as the
internal control. Importantly, the upregulated HO-1 protein observed in
animals co-administered with gabapentin and morphine was suppressed
by different concentrations of anti-IL-10 antibody (n=6, each). **p<0.01,
***p<0.001 compared with the saline group; ##p<0.01, ###p<0.001 com-
pared with the morphine group; $$p<0.01 compared with the gabapentin/
morphine group
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downregulation of pro-inflammatory cytokine TNF-α, IL-1β
and IL-6 expression and upregulation of anti-inflammatory
cytokine IL-10 expression in the rat spinal cord. Improvement
of the analgesic effects of morphine by gabapentin was par-
tially blocked by co-administration of anti-IL-10 antibody and
the HO-1 antagonist ZnPP. Neutralisation of the IL-10 anti-
body reversed the gabapentin-induced increase in HO-1 ex-
pression and inhibition of pro-inflammatory cytokines expres-
sion, suggesting that the HO-1 pathway is involved in
gabapentin-mediated induction of IL-10 expression. These
results suggested that the suppressive effect of gabapentin
co-injection on pro-inflammatory cytokine production in
morphine-injected rats may act via increasing IL-10 and
HO-1 protein expression. Several studies have shown that
the mRNA and protein levels of the pro-inflammatory
cytokines TNF-α, IL-1β and IL-6 increased following chron-
ic morphine injection and neuropathic pain (Rittner et al.
2005). The release of pro-inflammatory cytokines is a conse-
quence of chronic morphine exposure, which resulted in the
reduction of the anti-nociceptive effect of morphine. Our
results suggest that the gabapentin enhancement of the anti-
nociceptive effect of morphine in the neuropathic pain model
in rats is related to an inhibition of spinal inflammation.
IL-10 was first described as an inhibitor of cytokine syn-
thesis, and it was subsequently demonstrated that IL-10 atten-
uates nociceptive effects by inhibiting spinal glia activation
and the production of pro-inflammatory cytokines in an ani-
mal model (Niu et al. 2012). Furthermore, IL-10 abolishes the
mechanical hyperalgesia induced by carrageenan administra-
tion in the hind paw of rats. An IL-10-encoding adenoviral
Fig. 5 HO-1 antagonist zinc protoporphyrin reversed the gabapentin-
induced upregulation of heme oxygenase-1 (HO-1) expression and po-
tentiated the anti-nociceptive effect of morphine in gabapentin/morphine-
co-injected SNL rats. aWestern blotting analysis of HO-1 in the rat spinal
dorsal horns. β-actin was used as the loading control. The relative band
densities for HO-1 after different treatments. Time course of tail–flick test
(b) and Von Frey latencies (c) in SNL rats. The maximum anti-
nociceptive effect of morphine occurred on days 1–2. From days 4–7, there
was no difference between the morphine and saline-treated animals. When
gabapentin was co-administered with morphine, it prevented morphine
tolerance. In addition, ZnPP partially reversed the potentiating effect of
gabapentin on morphine in SNL rats (n=6, each). *p<0.05, ***p<0.001
compared with the saline group; ###p<0.001 compared with the morphine-
injected group; $p<0.05, $$p<0.01 $$$p<0.001 compared with the
gabapentin/morphine-injected group
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vector not only attenuated the development of tolerance,
hyperalgesia and allodynia, it also potentiated the analgesia
effect of morphine (Milligan et al. 2005). Chronic morphine
treatment has been shown to not alter IL-10 mRNA expres-
sion levels and to even reduce lippolysaccharide (LPS)-in-
duced IL-10 secretion (Nelson and Lysle 2001; Messmer et al.
2006). In our study, an increase in IL-10 protein levels was
observed in the spinal cord of gabapentin/morphine co-
administered neuropathic pain rats. Moreover, daily IL-10
(5 μg) i.t. injections significantly improved the anti-
nociceptive effect of morphine. Taken together, these results
strongly indicated that the inhibitory effect of IL-10 activation
and cytokine production are responsible for the neuroinflam-
mation induced by chronic morphine injection in neuropathic
pain rats. Consistent with this finding, a neutralising anti-IL-
10 antibody was found to counteract the anti-nociceptive
effects of gabapentin in morphine-tolerant neuropathic pain
rats.
Previous studies have shown that IL-10 exerts its anti-
inflammatory effects via the upregulation of HO-1 expression
(Gomez-Hurtado et al. 2011). The anti-inflammatory effects
of HO-1 have been demonstrated in several neuropathic and
inflammatory pain models (Hervera et al. 2012). HO-1 induc-
tion by epibatidine exhibits anti-nociceptive and anti-
i n f l amma t o r y e f f e c t s v i a t h e a c t i v a t i o n o f
methyllycaconitine-sensitive nAChRs (Egea et al. 2009).
HO-1 mediates the anti-inflammatory effects of acute alcohol
on IL-10 activation in monocytes (Milligan et al. 2005; Rittner
et al. 2005). These results showed that HO-1 plays a crucial
role in the host defence mechanism against inflammation;
HO-1 catabolises heme and generates the antioxidants biliver-
din and bilirubin, which protects against tissue injury-induced
inflammation (Rosa et al. 2008). In addition, a recent study
indicated that anti-IL-10 antibody dose-dependently reversed
the amitriptyline-induced HO-1 expression in amitriptyline/
morphine co-infused rats (Tai et al. 2009). Inhibition of HO-1
protein synthesis or activity significantly reversed the inhibi-
tory effect of IL-10 on production of TNF-α induced by
lipopolysaccharide (LPS; Lee and Chau 2002). In IL-10
knock-out mice, the expression of HO-1 was to a lower extent
than in corresponding wild-type mice under 24 h post-
ischemia (Perez-de-Puig et al. 2013). Treatment with HO-1
improved the local anti-nociceptive effects of morphine dur-
ing chronic inflammatory and neuropathic pain in mice
(Hervera et al. 2013). In our current study, we found that
gabapentin/morphine co-injection significantly increased IL-
10 and HO-1 expression and that it decreased the protein
levels of the pro-inflammatory cytokines TNF-α, IL-1β, IL-
6. In contrast, inhibition of IL-10 or HO-1 expression signif-
icantly downregulated HO-1 expression and increased
TNF-α, IL-1β and IL-6 protein levels. Moreover, the HO-1
expression was transcriptionally induced by IL-6 in a time and
dose-dependent manner (Tron et al. 2006). These results sug-
gested a role of HO-1 in the anti-inflammatory effect of IL-10
in gabapentin/morphine-coinjected SNL rats. Taken together,
HO-1 may be responsible for the protective effects of IL-10;
however, the detail mechanisms remain undetermined.
Several studies have demonstrated that gabapentin en-
hanced the anti-nociceptive effect of morphine in neuropathic
pain and visceral pain rats (Smiley et al. 2004; De la O-
Arciniega et al. 2009). The combination of gabapentin and
morphine, which were ineffective alone, produced a signifi-
cant analgesic effect in an animal writhing model of pain
(Meymandi and Sepehri 2008). Gabapentin alone did not
produce an anti-nociceptive effect, whereas the combined
treatment of morphine and gabapentin completely decreased
allodynia behaviour at 30 min post-injection, an effect that
persisted until 120min in neuropathic pain induced by chronic
constriction injury in rat (De la O-Arciniega et al. 2009).
Moreover, the anti-nociceptive effect induced by gabapentin
Fig. 6 Protein levels for tumor
necrosis factor-α (TNF-α),
interleukin (IL)-1β and IL-6 were
measured in the different groups.
Anti-interleukin-10 antibody and
heme oxygenase-1 antagonist
zinc protoporphyrin reversed the
suppressive effect of gabapentin
on pro-inflammatory cytokine
production (n=6, each).
***p<0.001 compared with the
saline-injected group; ###p<0.001
compared with the morphine-
injected group; $$p<0.01
compared with the saline,
morphine and gabapentin/
morphine-injected group
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may be inhibiting via the release of an inflammatory mediator.
Intrathecal gabapentin increased IL-10 expression and
inhibited the expression of the pro-inflammatory cytokines
TNF-α, IL-1β and IL-6 in a rat model of neuropathic pain
(Lee et al. 2013). Our previous study found that gabapentin
enhanced the morphine anti-nociceptive effect during acute
and chronic morphine treatments via IL-10 and that anti-IL-10
antibody reversed the effects of gabapentin on morphine.
Similarly, gabapentin was shown to diminish CX3CL1 sig-
nalling and spinal microglia activation induced by joint in-
flammation (Yang et al. 2012). Moreover, it has been demon-
strated that the degree of neuroinflammation induced by neu-
ropathy combined with chronic administration in nerve-
injured rats was higher compared to the neuroinflammation
induced by neuropathy alone (Raghavendra et al. 2002). This
suggested that neuroinflammation is a common mechanism in
both neuropathy-induced and chronic morphine-induced glial
activation (Raghavendra et al. 2004; Liu et al. 2011). In the
current study, daily anti-IL-10 and HO-1 antibody injection
produced significant pro-inflammatory cytokine expression
and attenuated the anti-nociceptive effect of gabapentin in
morphine-tolerant neuropathic pain rats. Conversely, daily
IL-10 (5 μg)/morphine injections produced a significant en-
hancement of the anti-nociceptive effect compared with mor-
phine injection alone in rats. Thus, the increased pro-
inflammatory cytokines expression observed in morphine-
tolerant rats contributes to the development of allodynia in-
duced by neuropathic pain.Moreover, morphine tolerance and
the inhibition of pro-inflammatory cytokine expression can
potentiate the anti-nociceptive effects of gabapentin on mor-
phine. Based on our study, intrathecally administered
gabapentin enhances IL-10, HO-1 expression and counteracts
morphine tolerance-induced neuroinflammation and may be
responsible for preventing neuropathic pain and inhibiting
morphine tolerance-induced pro-inflammatory cytokine ex-
pression in the rat spinal cord. However, further studies are
required to elucidate the underlying mechanism of i.t.
gabapentin action and the precise mechanism by which
gabapentin induces the upregulation of IL-10 and HO-1
expression.
Consequently, co-injection of gabapentin/morphine atten-
uatedmorphine tolerance in neuropathic pain rats.We propose
that the effect of gabapentin may be due, at least in part, to the
upregulated expression of anti-inflammatory cytokine IL-10
and a stress-induced protein HO-1 in the spinal cord, which
results in the inhibited expression of pro-inflammatory cyto-
kines TNF-α, IL-1β and IL-6 in morphine-tolerant rat spinal
cords. Thus, we suggest that gabapentin may be used as an
adjuvant in combination with opioids for the treatment of
chronic neuropathic pain conditions and for treatment of pa-
tients who require long-term opioid administration for pain
management in clinical practice. Taken together, these find-
ings may explain why gabapentin plays an important role in
the treatment of chronic neuropathic pain via systemic admin-
istration. The systemic effect and mechanisms of action of
gabapentin in morphine tolerance development and neuro-
pathic pain requires further investigation.
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